ADDITIONAL INFORMATION 21 21.1.6 TERMS GOVERNING ANY RIGHT OF ACQUISITION AND/OR ANY OBLIGATION ATTACHED TO SUBSCRIBED BUT NOT PAID-UP CAPITAL The table below sets forth the resolutions regarding issuance of shares, and stock options of the mixed general shareholders’ meeting held on April 12, 2018: Purpose Maximum amount Period of validity Global maximum Use of the Residual maximum amount in euros delegations amount in euros Delegation of powers given to the Board of Capital increase: 26 months i.e. until — Directors in order to issue ordinary shares (1) Maximum 75% of June 12, 2020 giving right, as the case may be, to ordinary the share capital shares or the allocation of debt securities (of at the date of the the company or a company of the group), and/ 2018 Shareholder’s or securities giving a right to ordinary shares Meeting i.e. (of the company or a company of the group) €454,391.69 without preferential subscription rights by Debt instruments public offering in accordance with the provisions giving access to of articles L.225-129-2, L.225-136 and L.228- equity securities: 92 of the Commercial Code (15 resth olution). €50,000,000 Delegation of powers given to the Board of Capital increase: 26 months i.e. until — Directors in order to issue ordinary shares Maximum 20% of June 12, 2020 giving right, as the case may be, to ordinary the share capital shares or the allocation of debt securities (of at the date of the the company or a company of the group), and/ Shareholder’s or securities giving a right to ordinary shares (of Meeting i.e. the company or a company of the group) without €121,171.12 preferential subscription rights as remuneration Debt instruments for the securities contributed in the context of a giving access to public exchange offering in accordance with the equity securities: provisions of articles L.225-129-2, L.225-135, €50,000,000 L.225-148 and L.228-92 of the Commercial Code (16 resoth lution). Delegation of powers given to the Board of Capital increase: 26 months i.e. until Capital increase: Directors in order to issue ordinary shares (1) Maximum20% of June 12, 2020 100%of the share — giving right, as the case may be, to ordinary the sharecapital capital at the Capital increase: shares or the allocation of debt securities (of at the date of the date of the 2018 €605,855.58 the company or a company of the group), and/ Shareholder’s Shareholder’s or securities giving a right to ordinary shares Meeting i.e. Debt instruments Meeting i.e. €605,855.58 giving access to (of the company or a company of the group) €121,171.12 and equity securities: without preferential subscription rights by an limited to 20% of the Debt instruments €50,000,000 offer referred to at section I I of article L.411-2 ofshare capital per year giving access to the Monetary and Financial Code in accordance Debt instruments equity securities: with the provisions of articles L.225-129-2, giving access to €50,000,000 L.225-135, L.225-136 and L.228-92 of the equity securities: Commercial Code (17 resolution).th €50,000,000 Authorization given to the Board of Directors, Capital increase: — for each of the issue of ordinary shares (2) or Maximum 10 % of securities giving right to the capital decided the share capital pursuant to the application of the fifteenth and of the company seventeenth resolutions set out hereabove, (such as it stands as to derogate from the conditions for the at the date of the determination of the price provided for by implementation of the fifteenth and seventeenth resolutions in this authorisation accordance with the provisions of article L.225- hereof) per twelve- 136, 1° of the Commercial Code (18 resolution).th month period at the time of the issue. Delegation given to the Board of Directors in Capital increase: 26 months i.e. until — order to increase the capital through the issue of 10%of theshare June 12, 2020 ordinary shares and/or securities giving right to capital at the date the capital, subject to a limitation of 10 % of theof the Shareholder’s capital in view of remunerating contributions Meeting i.e. in kind of shares or securities giving right to €60,585.56 the capital in accordance with the provisions of Debt instruments articles L.225-129-2, L.225-147 and L.228-92 giving access to of the Commercial Code (20 resolutith on). equity securities: €50,000,000 GENSIGHT BIOLOGICS – 2017 Registration Document– 221